Skopos Labs, Inc. Kymera Therapeutics, Inc. Transaction History
Skopos Labs, Inc.
- $497 Million
- Q2 2025
A detailed history of Skopos Labs, Inc. transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Skopos Labs, Inc. holds 6 shares of KYMR stock, worth $239. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6
Previous 6
-0.0%
Holding current value
$239
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding KYMR
# of Institutions
217Shares Held
72.2MCall Options Held
178KPut Options Held
64.6K-
Price T Rowe Associates Inc Baltimore, MD6.86MShares$273 Million0.03% of portfolio
-
Baker Bros. Advisors LP New York, NY6.65MShares$265 Million2.94% of portfolio
-
Avoro Capital Advisors LLC New York, NY6.56MShares$261 Million5.22% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.62MShares$224 Million0.0% of portfolio
-
Bvf Inc San Francisco, CA5.5MShares$219 Million9.44% of portfolio
About Kymera Therapeutics, Inc.
- Ticker KYMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,705,800
- Market Cap $2.18B
- Description
- Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...